NCT07838974
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07838974
Title Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Southern California
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.